Gene: CD82
Official Full Name: CD82 moleculeprovided by HGNC
Gene Summary: This metastasis suppressor gene product is a membrane glycoprotein that is a member of the transmembrane 4 superfamily. Expression of this gene has been shown to be downregulated in tumor progression of human cancers and can be activated by p53 through a consensus binding sequence in the promoter. Its expression and that of p53 are strongly correlated, and the loss of expression of these two proteins is associated with poor survival for prostate cancer patients. Two alternatively spliced transcript variants encoding distinct isoforms have been found for this gene. [provided by RefSeq, Jul 2008]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO02190 | CD82 Knockout cell line (HeLa) | Human | CD82 | 1:3~1:6 | Negative | Online Inquiry |
KO02191 | CD82 Knockout cell line (HCT 116) | Human | CD82 | 1:2~1:4 | Negative | Online Inquiry |
KO02192 | CD82 Knockout cell line (HEK293) | Human | CD82 | 1:3~1:6 | Negative | Online Inquiry |
KO02193 | CD82 Knockout cell line (A549) | Human | CD82 | 1:3~1:4 | Negative | Online Inquiry |
CD82 Gene Knockout Cell Lines are genetically engineered cell lines specifically designed to lack the expression of the CD82 gene, also known as the metastasis suppressor gene. This product serves as a vital tool for researchers aiming to investigate the roles and mechanisms of CD82 in various biological processes, particularly those related to cancer metastasis and cell signaling pathways.
The key function of these knockout cell lines revolves around their ability to enable researchers to systematically study the effects of CD82 deficiency on cell behavior, including proliferation, adhesion, migration, and invasion. By removing this gene, scientists can elucidate the involvement of CD82 in cellular mechanisms and its potential role in tumor progression and metastatic processes, providing insights into how tumor cells interact with their microenvironment.
The scientific importance of CD82 Gene Knockout Cell Lines is significant in both basic research and clinical applications. In research settings, they allow for fundamental discoveries related to cancer biology, immune response, and cellular communication. Clinically, understanding the role of CD82 can lead to new therapeutic strategies, targeting pathways influenced by this gene, thus contributing to the development of novel anti-metastatic therapies.
What sets our CD82 Gene Knockout Cell Lines apart from alternative products in the market is our use of precise genome-editing technologies that ensure high specificity and efficiency during the knockout process. This leads to consistent and reproducible results, which are crucial for experimental validation. Additionally, our cell lines are thoroughly characterized, ensuring researchers are receiving well-documented and reliable products.
By choosing our CD82 Gene Knockout Cell Lines, researchers and clinicians gain access to a robust tool that can enhance their studies and potentially lead to groundbreaking discoveries in cancer research. With a commitment to quality and innovation, our company leverages years of expertise in cellular biology to provide superior biological products that empower scientific advancements.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.